Trial Profile
A Study Comparing Amphilimus-Eluting Stent (Cre8) With 3-6 Months Of Dual Antiplatelet Therapy To A Zotarolimus-Eluting Stent (Resolute Integrity) With 3-12 Months Of Dual Antiplatelet Therapy In The Complex Setting Of Troponin Negative Diabetes Patients: Utrecht Cre8 (U-Cre8) Registry.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Feb 2017
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Zotarolimus
- Indications Restenosis
- Focus Therapeutic Use
- 08 Feb 2017 New trial record